Proteomics International Laboratories Ltd (ASX:PIQ)

Market Cap	23.15M -52.1%
Revenue (ttm)	3.37M +1.7%
Net Income	-8.56M
EPS	-0.06
Shares Out	165.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,988
Open	0.1300
Previous Close	0.1400
Day's Range	0.1300 - 0.1350
52-Week Range	0.0980 - 0.8600
Beta	-0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 24, 2026

About ASX:PIQ

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India. It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes. The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which ha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PIQ

Financial Performance

In fiscal year 2026, ASX:PIQ's revenue was 3.37 million, an increase of 1.75% compared to the previous year's 3.31 million. Losses were -8.56 million, 5.48% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error